_:n4464ede3068d4c36a4a4adb490c20b3fxb4
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>
<https://www.esmo.org/oncology-news/EMA-Recommends-Granting-a-Conditional-Marketing-Authorisation-for-Lorlatinib>